The dollar bounced on Tuesday after the COVID-19 vaccine trial reported encouraging data, lifting market appetite for risky currencies.
The euro surged against the dollar and the Swiss franc after Germany and France proposed for a 500 billion euro recovery fund for European regions hardest hit by the pandemic.
Commodity currencies and risky assets also rallied. This came after oil prices rebounded from losses and as U.S. drugmaker Moderna reported positive data from their initial vaccine trials.
The euro stood at 1.0911 against the dollar on Tuesday, while the British pound climbed to $1.2206.
The dollar traded at 107.44 on the yen.
Despite the positive market mood, the resurgence of coronavirus infections in certain parts of the world still worried investors.
In the onshore market, the Chinese yuan steadied at 7.1069 on the dollar. However, currency traders remain wary amid the rising conflict between China and the United States.
The Australian dollar stood at $0.6527, nearing a one-week high, while the New Zealand dollar traded at $0.6042.
The Dollar fell to two-year lows on Friday, heading to its lowest decline in 10 years as concerns mounted over the economic recovery of the U.S. amid a second resurgence of the COVID-19 pandemic. The Dollar index plunged to 92.777, on course ...
The dollar was briefly lifted on Thursday after the U.S. Federal Reserve offered no concrete clues about its next course of action, while investors hoped for an easy policy as the coronavirus resurgence stalled economic recovery. The dollar ...
Asian stocks advanced on the prospect of ultra-easy monetary policy as the U.S. Federal Reserve kept interest rates near zero. Fed deemed it necessary to salvage the ailing economy, dragging the dollar down to a two-year low. The target range ...
The dollar sat near two-year lows on Wednesday as the United States struggled to control the coronavirus outbreak, breaking hopes for a fast economic recovery. The gloomy outlook for the U.S. economy is expected to urge the Federal Reserve ...
Britain on Wednesday signed a supply deal for up to 60 million doses of a possible COVID-19 vaccine that is being developed by pharmaceutical companies GlaxoSmithKline (GSK) and Sanofi. The financial details of the agreement were not disclosed. However, ...